MTOR and renal cell carcinoma: Temsirolimus, a distinct mTOR inhibitor analogous to everolimus, was recognized in 2007 as an advanced treatment for renal cell carcinoma.36Temsirolimus additionally binds to FK506-binding proteins and the subsequent compound binds to mTOR and inhibits its effect on G1 phase progression of the cell cycle, cell growth, and proliferation.